Therapy of X-linked adrenoleukodystrophy

References

• Powers JM, Schaumburg HH. The adrenal cortex in adreno-leukodystrophy. Arch. Pathol.96(5), 305–310 (1973).
   PubMedGoogle Scholar
• Igarashi M, Schaumburg HH, Powers J, Kishmoto Y, Kolodny E, Suzuki K. Fatty acid abnormality in adrenoleukodystrophy. J. Neurochem.26(4), 851–860 (1976).
   PubMedGoogle Scholar
• Budka H, Sluga E, Heiss WD. Spastic paraplegia associated with Addison’s disease: adult variant of adreno-leukodystrophy. J. Neurol.213(3), 237–250 (1976).
   PubMedGoogle Scholar
• Griffin JW, Goren E, Schaumburg H, Engel WK, Loriaux L. Adrenomyeloneuropathy: a probable variant of adrenoleukodystrophy. I. Clinical and endocrinologic aspects. Neurology27(12), 1107–1113 (1977).
   PubMedGoogle Scholar
• Moser AB, Kreiter N, Bezman L et al. Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. Ann. Neurol.45(1), 100–110 (1999).
   PubMed Web of Science ®Google Scholar
• Fanconi A, Prader A, Isler W, Luethy F, Siebenmann R. [Addison’s disease with cerebral sclerosis in childhood. A hereditary syndrome transmitted through chromosome X?]. Helv. Paediatr. Acta18, 480–501 (1963).
   PubMedGoogle Scholar
• Migeon BR, Moser HW, Moser AB, Axelman J, Sillence D, Norum RA. Adrenoleukodystrophy: evidence for X linkage, inactivation, and selection favoring the mutant allele in heterozygous cells. Proc. Natl Acad. Sci. USA78(8), 5066–5070 (1981).
   PubMedGoogle Scholar
• Mosser J, Douar AM, Sarde CO et al. Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature361(6414), 726–730 (1993).
   PubMed Web of Science ®Google Scholar
• Aubourg P, Mosser J, Douar AM, Sarde CO, Lopez J, Mandel JL. Adrenoleukodystrophy gene: unexpected homology to a protein involved in peroxisome biogenesis. Biochimie75(3–4), 293–302 (1993).
   PubMedGoogle Scholar
• Bezman L, Moser AB, Raymond GV et al. Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. Ann. Neurol.49(4), 512–517 (2001).
   PubMed Web of Science ®Google Scholar
• Moser HW. Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain120(Pt 8), 1485–1508 (1997).
   PubMedGoogle Scholar
• Berger J, Molzer B, Fae I, Bernheimer H. X-linked adrenoleukodystrophy (ALD): a novel mutation of the ALD gene in 6 members of a family presenting with 5 different phenotypes. Biochem. Biophys. Res. Commun.205(3), 1638–1643 (1994).
   PubMed Web of Science ®Google Scholar
• Moser HW, Mahmood A, Raymond GV. X-linked adrenoleukodystrophy. Nat. Clin. Pract. Neurol.3(3), 140–151 (2007).
   PubMedGoogle Scholar
• Weller M, Liedtke W, Petersen D, Opitz H, Poremba M. Very-late-onset adrenoleukodystrophy: possible precipitation of demyelination by cerebral contusion. Neurology42(2), 367–370 (1992).
   PubMed Web of Science ®Google Scholar
• Ito M, Blumberg BM, Mock DJ et al. Potential environmental and host participants in the early white matter lesion of adreno-leukodystrophy: morphologic evidence for CD8 cytotoxic T cells, cytolysis of oligodendrocytes, and CD1-mediated lipid antigen presentation. J. Neuropathol. Exp. Neurol.60(10), 1004–1019 (2001).
   PubMed Web of Science ®Google Scholar
• Powers JM, Liu Y, Moser AB, Moser HW. The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications. J. Neuropathol. Exp. Neurol.51(6), 630–643 (1992).
   PubMedGoogle Scholar
• Kumar AJ, Kohler W, Kruse B et al. MR findings in adult-onset adrenoleukodystrophy. AJNR Am.J. Neuroradiol.16(6), 1227–1237 (1995).
   PubMed Web of Science ®Google Scholar
• Brennemann W, Kohler W, Zierz S, Klingmuller D. Occurrence of adrenocortical insufficiency in adrenomyeloneuropathy. Neurology47(2), 605 (1996).
   PubMedGoogle Scholar
• Brennemann W, Kohler W, Zierz S, Klingmuller D. Testicular dysfunction in adrenomyeloneuropathy. Eur. J. Endocrinol.137(1), 34–39 (1997).
   PubMedGoogle Scholar
• van Geel BM, Bezman L, Loes DJ, Moser HW, Raymond GV. Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy. Ann. Neurol.49(2), 186–194 (2001).
   PubMed Web of Science ®Google Scholar
• Moser HW, Loes DJ, Melhem ER et al. X-linked adrenoleukodystrophy: overview and prognosis as a function of age and brain magnetic resonance imaging abnormality. A study involving 372 patients. Neuropediatrics31(5), 227–239 (2000).
   PubMedGoogle Scholar
• Restuccia D, Di Lazzaro V, Valeriani M et al. Neurophysiological abnormalities in adrenoleukodystrophy carriers. Evidence of different degrees of central nervous system involvement. Brain120(Pt 7), 1139–1148 (1997).
   PubMedGoogle Scholar
• Fatemi A, Barker PB, Ulug AM et al. MRI and proton MRSI in women heterozygous for X-linked adrenoleukodystrophy. Neurology60(8), 1301–1307 (2003).
   PubMed Web of Science ®Google Scholar
• Stockler S, Millner M, Molzer B, Ebner F, Korner E, Moser HW. Multiple sclerosis-like syndrome in a woman heterozygous for adrenoleukodystrophy. Eur. Neurol.33(5), 390–392 (1993).
   PubMedGoogle Scholar
• Jung HH, Wimplinger I, Jung S, Landau K, Gal A, Heppner FL. Phenotypes of female adrenoleukodystrophy. Neurology68(12), 960–961 (2007).
   PubMedGoogle Scholar
• Moser HW, Moser AE, Trojak JE, Supplee SW. Identification of female carriers of adrenoleukodystrophy. J. Pediatr.103(1), 54–59 (1983).
   PubMedGoogle Scholar
• Kemp S, Pujol A, Waterham HR et al.ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations. Hum. Mutat.18(6), 499–515 (2001).
   PubMed Web of Science ®Google Scholar
• Boehm CD, Cutting GR, Lachtermacher MB, Moser HW, Chong SS. Accurate DNA-based diagnostic and carrier testing for X linked adrenoleukodystrophy. Mol. Genet. Metab.66(2), 128–136 (1999).
   PubMedGoogle Scholar
• Vianello M, Manara R, Betterle C, Tavolato B, Mariniello B, Giometto B. X linked adrenoleukodystrophy with olivopontocerebellar atrophy. Eur J. Neurol.12(11), 912–914 (2005).
   PubMedGoogle Scholar
• Moser HW, Köhler W, Borel J. The many faces of X-linked adrenoleukodystrophy: implications for pathogenesis and the evaluation of therapy. In: Functions and Biogenesis of Peroxisomes in Relation to Human Disease. Wanders RJA, Schutgens RBH, Tabak H (Eds). Springer, North-Holland, Amsterdam, Oxford, New York, Tokyo 227–246 (1995).
   Google Scholar
• Traboulsi EI, Maumenee IH. Ophthalmologic manifestations of X-linked childhood adrenoleukodystrophy. Ophthalmology94(1), 47–52 (1987).
   PubMedGoogle Scholar
• Wray SH, Cogan DG, Kuwabara T, Schaumburg HH, Powers JM. Adrenoleukodystrophy with disease of the eye and optic nerve. Am. J. Ophthalmol.82(3), 480–485 (1976).
   PubMedGoogle Scholar
• Watkins PA. Fatty acid activation. Prog. Lipid Res.36(1), 55–83 (1997).
   PubMed Web of Science ®Google Scholar
• Kemp S, Wanders RJ. X-linked adrenoleukodystrophy: very long-chain fatty acid metabolism, ABC half-transporters and the complicated route to treatment. Mol. Genet. Metab.90(3), 268 –276 (2007).
   PubMed Web of Science ®Google Scholar
• Wanders RJ, van Roermund CW, van Wijland MJ et al. Direct demonstration that the deficient oxidation of very long chain fatty acids in X-linked adrenoleukodystrophy is due to an impaired ability of peroxisomes to activate very long chain fatty acids. Biochem. Biophys. Res. Commun.153(2), 618–624 (1988).
   PubMed Web of Science ®Google Scholar
• Wanders RJ, Visser WF, van Roermund CW, Kemp S, Waterham HR. The peroxisomal ABC transporter family. Pflugers Arch.453(5), 719–734 (2007).
   PubMed Web of Science ®Google Scholar
• Kemp S, Valianpour F, Denis S et al. Elongation of very long-chain fatty acids is enhanced in X-linked adrenoleukodystrophy. Mol. Genet. Metab.84(2), 144–151 (2005).
   PubMed Web of Science ®Google Scholar
• Sanders RJ, Ofman R, Duran M, Kemp S, Wanders RJ. Omega-oxidation of very long-chain fatty acids in human liver microsomes. Implications for X-linked adrenoleukodystrophy. J. Biol. Chem.281(19), 13180–13187 (2006).
   PubMed Web of Science ®Google Scholar
• Ferdinandusse S, Denis S, Van Roermund CW, Wanders RJ, Dacremont G. Identification of the peroxisomal b-oxidation enzymes involved in the degradation of long-chain dicarboxylic acids. J. Lipid Res.45(6), 1104–1111 (2004).
   PubMedGoogle Scholar
• Korman SH, Mandel H, Gutman A. Characteristic urine organic acid profile in peroxisomal biogenesis disorders. J. Inherit. Metab. Dis.23(4), 425–428 (2000).
   PubMed Web of Science ®Google Scholar
• Ho JK, Moser H, Kishimoto Y, Hamilton JA. Interactions of a very long chain fatty acid with model membranes and serum albumin. Implications for the pathogenesis of adrenoleukodystrophy. J. Clin. Invest.96(3), 1455–1463 (1995).
   PubMed Web of Science ®Google Scholar
• Hein S, Schonfeld P, Kahlert S, Reiser G. Toxic effects of X-linked adrenoleukodystrophy-associated, very long chain fatty acids on glial cells and neurons from rat hippocampus in culture. Hum. Mol. Genet.17(12), 1750–1761 (2008).
   PubMedGoogle Scholar
• Fourcade S, Lopez-Erauskin J, Galino J et al. Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy. Hum. Mol. Genet.17(12), 1762–1773 (2008).
   PubMed Web of Science ®Google Scholar
• Sarde CO, Mosser J, Kioschis P et al. Genomic organization of the adrenoleukodystrophy gene. Genomics22(1), 13–20 (1994).
   PubMed Web of Science ®Google Scholar
• Heinzer AK, McGuinness MC, Lu JF et al. Mouse models and genetic modifiers in X-linked adrenoleukodystrophy. Adv. Exp. Med. Biol.544, 75–93 (2003).
   PubMedGoogle Scholar
• Dodd A, Rowland SA, Hawkes SL, Kennedy MA, Love DR. Mutations in the adrenoleukodystrophy gene. Hum. Mutat.9(6), 500–511 (1997).
   PubMedGoogle Scholar
• Gartner J, Braun A, Holzinger A, Roerig P, Lenard HG, Roscher AA. Clinical and genetic aspects of X-linked adrenoleukodystrophy. Neuropediatrics29(1), 3–13 (1998).
   PubMedGoogle Scholar
• Kok F, Neumann S, Sarde CO et al. Mutational analysis of patients with X-linked adrenoleukodystrophy. Hum. Mutat.6(2), 104–115 (1995).
   PubMedGoogle Scholar
• Maestri NE, Beaty TH. Predictions of a 2-locus model for disease heterogeneity: application to adrenoleukodystrophy. Am. J. Med. Genet.44(5), 576–582 (1992).
   PubMedGoogle Scholar
• Smith KD, Sack G, Beaty T et al. A genetic basis for the multiple phenotypes of X-linked adrenoleukodystrophy. Am. J. Med. Genet.49(suppl), 165 (1991).
   Google Scholar
• McGuinness MC, Griffin DE, Raymond GV, Washington CA, Moser HW, Smith KD. Tumor necrosis factor-α and X-linked adrenoleukodystrophy. J. Neuroimmunol.61(2), 161–169 (1995).
   PubMedGoogle Scholar
• Asheuer M, Pflumio F, Benhamida S et al. Human CD34+ cells differentiate into microglia and express recombinant therapeutic protein. Proc. Natl Acad. Sci. USA101(10), 3557–3562 (2004).
   PubMed Web of Science ®Google Scholar
• Linnebank M, Kemp S, Wanders RJ et al. Methionine metabolism and phenotypic variability in X-linked adrenoleukodystrophy. Neurology66(3), 442–443 (2006).
   PubMedGoogle Scholar
• Linnebank M, Semmler A, Kleijer WJ et al. The cystathionine β-synthase variant c.844_845ins68 protects against CNS demyelination in X-linked adrenoleukodystrophy. Hum. Mutat.27(10), 1063–1064 (2006).
   PubMedGoogle Scholar
• Korenke GC, Fuchs S, Krasemann E et al. Cerebral adrenoleukodystrophy (ALD) in only one of monozygotic twins with an identical ALD genotype. Ann. Neurol.40(2), 254–257 (1996).
   PubMedGoogle Scholar
• McGuinness MC, Lu JF, Zhang HP et al. Role of ALDP (ABCD1) and mitochondria in X-linked adrenoleukodystrophy. Mol. Cell Biol.23(2), 744–753 (2003).
   PubMed Web of Science ®Google Scholar
• Lu JF, Lawler AM, Watkins PA et al. A mouse model for X-linked adrenoleukodystrophy. Proc. Natl Acad. Sci. USA94(17), 9366–9371 (1997).
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Shinnoh N, Kondo A, Yamada T. Adrenoleukodystrophy protein-deficient mice represent abnormality of very long chain fatty acid metabolism. Biochem. Biophys. Res. Commun.232(3), 631–636 (1997).
   PubMedGoogle Scholar
• Forss-Petter S, Werner H, Berger J et al. Targeted inactivation of the X-linked adrenoleukodystrophy gene in mice. J. Neurosci. Res.50(5), 829–843 (1997).
   PubMedGoogle Scholar
• Pujol A, Hindelang C, Callizot N, Bartsch U, Schachner M, Mandel JL. Late onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse model for adrenomyeloneuropathy. Hum. Mol. Genet.11(5), 499–505 (2002).
   PubMed Web of Science ®Google Scholar
• Pujol A, Ferrer I, Camps C et al. Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy. Hum. Mol. Genet.13(23), 2997–3006 (2004).
   PubMed Web of Science ®Google Scholar
• Kassmann CM, Lappe-Siefke C, Baes M et al. Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes. Nat. Genet.39(8), 969–976 (2007).
   PubMed Web of Science ®Google Scholar
• Thoms S, Erdmann R. Peroxisomal matrix protein receptor ubiquitination and recycling. Biochim. Biophys. Acta1763(12), 1620–1628 (2006).
   PubMedGoogle Scholar
• Lledo B, Bernabeu R, Ten J, Galan FM, Cioffi L. Preimplantation genetic diagnosis of X-linked adrenoleukodystrophy with gender determination using multiple displacement amplification. Fertil. Steril.88(5), 1327–1333 (2007).
   PubMedGoogle Scholar
• Maier EM, Roscher AA, Kammerer S, Mehnert K, Conzelmann E, Holzinger A. Prenatal diagnosis of X-linked adrenoleukodystrophy combining biochemical, immunocytochemical and DNA analyses. Prenat. Diagn.19(4), 364–368 (1999).
   PubMedGoogle Scholar
• Moser AB, Moser HW. The prenatal diagnosis of X-linked adrenoleukodystrophy. Prenat. Diagn.19(1), 46–48 (1999).
   PubMedGoogle Scholar
• Stumpf DA, Hayward A, Haas R, Frost M, Schaumburg HH. Adrenoleukodystrophy. Failure of immunosuppression to prevent neurological progression. Arch. Neurol.38(1), 48–49 (1981).
   PubMedGoogle Scholar
• Naidu S, Bresnan MJ, Griffin D, O’Toole S, Moser HW. Childhood adrenoleukodystrophy. Failure of intensive immunosuppression to arrest neurologic progression. Arch. Neurol.45(8), 846–848 (1988).
   PubMedGoogle Scholar
• Korenke GC, Christen HJ, Kruse B, Hunneman DH, Hanefeld F. Progression of X-linked adrenoleukodystrophy under interferon-β therapy. J. Inherit. Metab. Dis.20(1), 59–66 (1997).
   PubMedGoogle Scholar
• Cappa M, Bertini E, del Balzo P, Cambiaso P, Di Biase A, Salvati S. High dose immunoglobulin IV treatment in adrenoleukodystrophy. J. Neurol. Neurosurg. Psychiatry57(Suppl.), 69–70; discussion 71 (1994).
   PubMedGoogle Scholar
• Mundy HR, Jones SJ, Hobart JC, Hanna MG, Lee PJ. A randomized controlled study of modified cobratoxin in adrenomyeloneuropathy. Neurology61(4), 528–530 (2003).
   PubMedGoogle Scholar
• Dubey P, Raymond GV, Moser AB, Kharkar S, Bezman L, Moser HW. Adrenal insufficiency in asymptomatic adrenoleukodystrophy patients identified by very long-chain fatty acid screening. J. Pediatr.146(4), 528–532 (2005).
   PubMedGoogle Scholar
• Kishimoto Y, Moser HW, Kawamura N, Platt M, Pallante SL, Fenselau C. Adrenoleukodystrophy: evidence that abnormal very long chain fatty acids of brain cholesterol esters are of exogenous origin. Biochem. Biophys. Res. Commun.96(1), 69–76 (1980).
   PubMedGoogle Scholar
• Tsuji S, Ohno T, Miyatake T, Suzuki A, Yamakawa T. Fatty acid elongation activity in fibroblasts from patients with adrenoleukodystrophy (ALD). J. Biochem.96(4), 1241–1247 (1984).
   PubMedGoogle Scholar
• Singh I, Moser AE, Moser HW, Kishimoto Y. Adrenoleukodystrophy: impaired oxidation of very long chain fatty acids in white blood cells, cultured skin fibroblasts, and amniocytes. Pediatr. Res.18(3), 286–290 (1984).
   PubMedGoogle Scholar
• Brown FR 3rd, Van Duyn MA, Moser AB et al. Adrenoleukodystrophy: effects of dietary restriction of very long chain fatty acids and of administration of carnitine and clofibrate on clinical status and plasma fatty acids. Johns Hopkins Med. J.151(4), 164–172 (1982).
   PubMedGoogle Scholar
• Moser AB, Borel J, Odone A et al. A new dietary therapy for adrenoleukodystrophy: biochemical and preliminary clinical results in 36 patients. Ann. Neurol.21(3), 240–249 (1987).
   PubMed Web of Science ®Google Scholar
• Rizzo WB, Phillips MW, Dammann AL et al. Adrenoleukodystrophy: dietary oleic acid lowers hexacosanoate levels. Ann. Neurol.21(3), 232–239 (1987).
   PubMedGoogle Scholar
• Rizzo WB, Leshner RT, Odone A et al. Dietary erucic acid therapy for X-linked adrenoleukodystrophy. Neurology39(11), 1415–1422 (1989).
   PubMed Web of Science ®Google Scholar
• Aubourg P, Adamsbaum C, Lavallard-Rousseau MC et al. A two-year trial of oleic and erucic acids (“Lorenzo’s oil”) as treatment for adrenomyeloneuropathy. N. Engl. J. Med.329(11), 745–752 (1993).
   PubMedGoogle Scholar
• Moser HW, Raymond GV, Dubey P. Adrenoleukodystrophy: new approaches to a neurodegenerative disease. JAMA294(24), 3131–3134 (2005).
   PubMed Web of Science ®Google Scholar
• Moser HW, Raymond GV, Koehler W et al. Evaluation of the preventive effect of glyceryl trioleate-trierucate (“Lorenzo’s oil”) therapy in X-linked adrenoleukodystrophy: results of two concurrent trials. Adv. Exp. Med. Biol.544, 369–387 (2003).
   PubMed Web of Science ®Google Scholar
• Moser HW, Raymond GV, Lu SE et al. Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo’s oil. Arch. Neurol.62(7), 1073–1080 (2005).
   PubMed Web of Science ®Google Scholar
• Moser HW. Therapy of X-linked adrenoleukodystrophy. NeuroRx3(2), 246–253 (2006).
   PubMedGoogle Scholar
• Sedlmayr P, Plecko B, Paschke E et al. Severely depressed natural killer cell activity of patients with adrenoleukodystrophy under treatment with Lorenzo’s oil. J. Inherit. Metab. Dis.18(1), 101–102 (1995).
   PubMedGoogle Scholar
• Kickler TS, Zinkham WH, Moser A, Shankroff J, Borel J, Moser H. Effect of erucic acid on platelets in patients with adrenoleukodystrophy. Biochem. Mol. Med.57(2), 125–133 (1996).
   PubMedGoogle Scholar
• van Geel BM, Assies J, Haverkort EB et al. Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with “Lorenzo’s oil”. J. Neurol. Neurosurg. Psychiatry67(3), 290–299 (1999).
   PubMed Web of Science ®Google Scholar
• Kaplan PW, Tusa RJ, Shankroff J, Heller J, Moser HW. Visual evoked potentials in adrenoleukodystrophy: a trial with glycerol trioleate and Lorenzo oil. Ann. Neurol.34(2), 169–174 (1993).
   PubMedGoogle Scholar
• Korenke GC, Hunneman DH, Kohler J, Stockler S, Landmark K, Hanefeld F. Glyceroltrioleate/glyceroltrierucate therapy in 16 patients with X-chromosomal adrenoleukodystrophy/adrenomyeloneuropathy: effect on clinical, biochemical and neurophysiological parameters. Eur. J. Pediatr.154(1), 64–70 (1995).
   PubMedGoogle Scholar
• Asano J, Suzuki Y, Yajima S et al. Effects of erucic acid therapy on Japanese patients with X-linked adrenoleukodystrophy. Brain Dev.16(6), 454–458 (1994).
   PubMedGoogle Scholar
• Neuringer M, Anderson GJ, Connor WE. The essentiality of n-3 fatty acids for the development and function of the retina and brain. Annu. Rev. Nutr.8, 517–541 (1988).
   PubMed Web of Science ®Google Scholar
• Köhler W, Solokowski P. Clinical Phenotypes, diagnosis and treatment of X-linked adrenoleukodystrophy with special emphasis on its manifestation in adulthood. In: Understanding and Treating Adrenoleukodystrophy – present state and future perspective. Berger J, Stöckler-Ipsiroglu S, Köhler W (Eds). SPS Verlagsgesellschaft, Heilbronn, 28–60 (2005).
   Google Scholar
• Hubbard WC, Moser AB, Tortorelli S, Liu A, Jones D, Moser H. Combined liquid chromatography-tandem mass spectrometry as an analytical method for high throughput screening for X-linked adrenoleukodystrophy and other peroxisomal disorders: preliminary findings. Mol. Genet. Metab.89(1–2), 185–187 (2006).
   PubMedGoogle Scholar
• Peters C, Charnas LR, Tan Y et al. Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood104(3), 881–888 (2004).
   PubMed Web of Science ®Google Scholar
• Aubourg P, Blanche S, Jambaque I et al. Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. N. Engl. J. Med.322(26), 1860–1866 (1990).
   PubMed Web of Science ®Google Scholar
• Schonberger S, Roerig P, Schneider DT, Reifenberger G, Gobel U, Gartner J. Genotype and protein expression after bone marrow transplantation for adrenoleukodystrophy. Arch. Neurol.64(5), 651–657 (2007).
   PubMedGoogle Scholar
• Malm G, Ringden O, Anvret M et al. Treatment of adrenoleukodystrophy with bone marrow transplantation. Acta Paediatr.86(5), 484–492 (1997).
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Isogai K, Teramoto T et al. Bone marrow transplantation for the treatment of X linked adrenoleukodystrophy. J. Inherit. Metab. Dis.23(5), 453–458 (2000).
   PubMedGoogle Scholar
• Wilken B, Dechent P, Brockmann K et al. Quantitative proton magnetic resonance spectroscopy of children with adrenoleukodystrophy before and after hematopoietic stem cell transplantation. Neuropediatrics34(5), 237–246 (2003).
   PubMedGoogle Scholar
• Beam D, Poe MD, Provenzale JM et al. Outcomes of unrelated umbilical cord blood transplantation for X-linked adrenoleukodystrophy. Biol. Blood Marrow Transplant.13(6), 665–674 (2007).
   PubMed Web of Science ®Google Scholar
• Baumann M, Korenke GC, Weddige-Diedrichs A et al. Haematopoietic stem cell transplantation in 12 patients with cerebral X-linked adrenoleukodystrophy. Eur J. Pediatr.162(1), 6–14 (2003).
   PubMedGoogle Scholar
• Shapiro E, Krivit W, Lockman L et al. Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. Lancet356(9231), 713–718 (2000).
   PubMed Web of Science ®Google Scholar
• Mahmood A, Raymond GV, Dubey P, Peters C, Moser HW. Survival analysis of haematopoietic cell transplantation for childhood cerebral X-linked adrenoleukodystrophy: a comparison study. Lancet Neurol.6(8), 687–692 (2007).
   PubMed Web of Science ®Google Scholar
• Krivit W, Aubourg P, Shapiro E, Peters C. Bone marrow transplantation for globoid cell leukodystrophy, adrenoleukodystrophy, metachromatic leukodystrophy, and Hurler syndrome. Curr. Opin. Hematol.6(6), 377–382 (1999).
   PubMedGoogle Scholar
• Gess A, Christiansen SP, Pond D, Peters C. Predictive factors for vision loss after hematopoietic cell transplant for X-linked adrenoleukodystrophy. J. AAPOS12(3), 273–276 (2008).
   PubMedGoogle Scholar
• Hitomi T, Mezaki T, Tomimoto H et al. Long-term effect of bone marrow transplantation in adult-onset adrenoleukodystrophy. Eur. J. Neurol.12(10), 807–810 (2005).
   PubMedGoogle Scholar
• Fitzpatrick AS, Loughrey CM, Johnston P et al. Haematopoietic stem-cell transplant for adult cerebral adrenoleukodystrophy. Eur. J. Neurol.15(3), e21–e22 (2008).
   PubMedGoogle Scholar
• Uziel G, Bertini E, Bardelli P, Rimoldi M, Gambetti M. Experience on therapy of adrenoleukodystrophy and adrenomyeloneuropathy. Dev. Neurosci.13(4–5), 274–279 (1991).
   PubMedGoogle Scholar
• Deforge D, Blackmer J, Garritty C et al. Male erectile dysfunction following spinal cord injury: a systematic review. Spinal Cord44(8), 465–473 (2006).
   PubMed Web of Science ®Google Scholar
• Garside S, Rosebush PI, Levinson AJ, Mazurek MF. Late-onset adrenoleukodystrophy associated with long-standing psychiatric symptoms. J. Clin. Psychiatry60(7), 460–468 (1999).
   PubMedGoogle Scholar
• Rosebush PI, Garside S, Levinson AJ, Mazurek MF. The neuropsychiatry of adult-onset adrenoleukodystrophy. J. Neuropsychiatry Clin. Neurosci.11(3), 315–327 (1999).
   PubMedGoogle Scholar
• Moser HW, Moser AB, Hollandsworth K, Brereton NH, Raymond GV. “Lorenzo’s oil” therapy for X-linked adrenoleukodystrophy: rationale and current assessment of efficacy. J. Mol. Neurosci.33(1), 105–113 (2007).
   PubMed Web of Science ®Google Scholar
• Berger J, Albet S, Bentejac M et al. The four murine peroxisomal ABC-transporter genes differ in constitutive, inducible and developmental expression. Eur J. Biochem.265(2), 719–727 (1999).
   PubMedGoogle Scholar
• Netik A, Forss-Petter S, Holzinger A, Molzer B, Unterrainer G, Berger J. Adrenoleukodystrophy-related protein can compensate functionally for adrenoleukodystrophy protein deficiency (X-ALD): implications for therapy. Hum. Mol. Genet.8(5), 907–913 (1999).
   PubMedGoogle Scholar
• Powers JM, Pei Z, Heinzer AK et al. Adreno-leukodystrophy: oxidative stress of mice and men. J. Neuropathol. Exp. Neurol.64(12), 1067–1079 (2005).
   PubMed Web of Science ®Google Scholar
• Vargas CR, Wajner M, Sirtori LR et al. Evidence that oxidative stress is increased in patients with X-linked adrenoleukodystrophy. Biochim. Biophys. Acta1688(1), 26–32 (2004).
   PubMed Web of Science ®Google Scholar
• Deon M, Sitta A, Barschak AG et al. Oxidative stress is induced in female carriers of X-linked adrenoleukodystrophy. J. Neurol. Sci.266(1–2), 79–83 (2008).
   PubMedGoogle Scholar
• Tolar J, Orchard PJ, Bjoraker KJ, Ziegler RS, Shapiro EG, Charnas L. N-acetyl-L-cysteine improves outcome of advanced cerebral adrenoleukodystrophy. Bone Marrow Transplant.39(4), 211–215 (2007).
   PubMed Web of Science ®Google Scholar
• Pai GS, Khan M, Barbosa E et al. Lovastatin therapy for X-linked adrenoleukodystrophy: clinical and biochemical observations on 12 patients. Mol. Genet. Metab.69(4), 312–322 (2000).
   PubMedGoogle Scholar
• Singh I, Khan M, Key L, Pai S. Lovastatin for X-linked adrenoleukodystrophy. N. Engl. J. Med.339(10), 702–703 (1998).
   PubMed Web of Science ®Google Scholar
• Singh I, Pahan K, Khan M. Lovastatin and sodium phenylacetate normalize the levels of very long chain fatty acids in skin fibroblasts of X-adrenoleukodystrophy. FEBS Lett.426(3), 342–346 (1998).
   PubMedGoogle Scholar
• Weinhofer I, Forss-Petter S, Zigman M, Berger J. Cholesterol regulates ABCD2 expression: implications for the therapy of X-linked adrenoleukodystrophy. Hum. Mol. Genet.11(22), 2701–2708 (2002).
   PubMedGoogle Scholar
• Pahan K, Sheikh FG, Namboodiri AM, Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J. Clin. Invest.100(11), 2671–2679 (1997).
   PubMed Web of Science ®Google Scholar
• Stanislaus R, Pahan K, Singh AK, Singh I. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci. Lett.269(2), 71–74 (1999).
   PubMed Web of Science ®Google Scholar
• Engelen M, Ofman R, Mooijer PA, Poll-The BT, Wanders RJ, Kemp S. Cholesterol-deprivation increases mono-unsaturated very long-chain fatty acids in skin fibroblasts from patients with X-linked adrenoleukodystrophy. Biochim. Biophys. Acta1781(3), 105–111 (2008).
   PubMedGoogle Scholar
• Benhamida S, Pflumio F, Dubart-Kupperschmitt A et al. Transduced CD34+ cells from adrenoleukodystrophy patients with HIV-derived vector mediate long-term engraftment of NOD/SCID mice. Mol. Ther.7(3), 317–324 (2003).
   PubMed Web of Science ®Google Scholar
• Priller J, Flugel A, Wehner T et al. Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. Nat. Med.7(12), 1356–1361 (2001).
   PubMed Web of Science ®Google Scholar